Moriyama H, Nakamura K, Sanda N, Fujiwara E, Seko S, Yamazaki A, Mizutani M, Sagami K, Kitano T
Hinyokika Kiyo. 1987 Jan;33(1):151-6.
Methylcobalamin (CH3-B12) was administrated in a dose of 6 mg per day (group A, 16 cases) or 12 mg per day (group B, 23 cases) for 16 weeks to patients with oligozoospermia. There was no difference between group A and group B regarding vitamin B12 concentrations in the serum or seminal fluid. CH3-B12 appeared to be transported to seminal fluid very efficiently. However, results from group A and group B did not differ with respect to this parameter. The efficacy rate for group A was 37.5% and that for group B was 39.1%. From these results, it was concluded that a long-term, high dose treatment of CH3-B12 was useful for the treatment of patients with oligozoospermia. Since the efficacy rates were not different between the two groups, 6 mg per day would be the recommended dose. Clinical adverse reactions were observed in one patient in each group. Drug-related laboratory adverse reactions were observed in only one patient in group B.
对少精子症患者，给予甲钴胺（CH3 - B12），A组16例，剂量为每日6毫克；B组23例，剂量为每日12毫克，治疗16周。A组和B组在血清或精液中的维生素B12浓度方面无差异。CH3 - B12似乎能非常有效地转运至精液中。然而，A组和B组在该参数方面的结果并无差异。A组的有效率为37.5%，B组为39.1%。从这些结果得出结论，长期、高剂量的CH3 - B12治疗对少精子症患者有效。由于两组有效率无差异，推荐剂量为每日6毫克。每组各有1例患者出现临床不良反应。B组仅1例患者出现与药物相关的实验室不良反应。
